BioCardia, Inc. (BCDA) stock
BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.02 (-2.06%)
Close on Nov 18, 2026Market cap $11.69MP/E –Yield –
BioCardia gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
BioCardia's gross profit for the twelve months ending Dec 31, 2021 was $1.02M, up 619.9% year over year. For fiscal 2021 it was $1.02M, up 619.9% from the year before. The highest annual figure on record is $1.02M in fiscal 2021.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $1.02M | +619.9% |
| FY2020 | Dec 31, 2020 | $141.00K | -59.9% |
| FY2019 | Dec 31, 2019 | $352.00K | +225.9% |
| FY2018 | Dec 31, 2018 | $108.00K | – |
| FY2017 | Dec 31, 2017 | -$211.00K | – |
| FY2016 | Dec 31, 2016 | -$170.00K | – |
| FY2015 | Dec 31, 2015 | -$157.00K | -353.2% |
| FY2012 | Dec 31, 2012 | $62.00K | +416.7% |
| FY2011 | Dec 31, 2011 | $12.00K | – |
| FY2010 | Dec 31, 2010 | $0 | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2021 | Dec 31, 2021 | $79.00K | +132.4% |
| Q3 FY2021 | Sep 30, 2021 | $821.00K | +2940.7% |
| Q2 FY2021 | Jun 30, 2021 | $69.00K | +102.9% |
| Q4 FY2020 | Dec 31, 2020 | $46.00K | -74.2% |
| Q3 FY2020 | Sep 30, 2020 | $34.00K | -80.0% |
| Q2 FY2020 | Jun 30, 2020 | $27.00K | – |
| Q1 FY2020 | Mar 31, 2020 | $34.00K | -69.1% |
| Q4 FY2019 | Dec 31, 2019 | $178.00K | – |
| Q3 FY2019 | Sep 30, 2019 | $170.00K | – |
| Q2 FY2019 | Jun 30, 2019 | -$105.00K | -201.0% |
| Q1 FY2019 | Mar 31, 2019 | $110.00K | +161.9% |
| Q4 FY2018 | Dec 31, 2018 | -$13.00K | – |
| Q3 FY2018 | Sep 30, 2018 | -$25.00K | – |
| Q2 FY2018 | Jun 30, 2018 | $104.00K | – |
| Q1 FY2018 | Mar 31, 2018 | $42.00K | – |
| Q4 FY2017 | Dec 31, 2017 | -$65.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$17.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$91.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$38.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$31.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$79.00K | – |
See a number that looks wrong?